Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Real-time Estimate Cboe BZX  -  01:53:51 2023-06-08 pm EDT
124.69 USD   -0.74%
06/07Insider Sell: Moderna
MT
06/07Pfizer, Moderna, BioNTech Sued for Alleged Patent Infringement Over COVID-19 Vaccine
MT
06/06Moderna, Pfizer hit with new patent lawsuits over COVID vaccines
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/02/2023 06/05/2023 06/06/2023 06/07/2023 06/08/2023 Date
130.51(c) 128.9(c) 126.9(c) 125.61(c) 124.1787 Last
2 357 539 3 206 071 2 491 424 3 161 355 1 473 739 Volume
+1.55% -1.23% -1.55% -1.02% -1.14% Change
More quotes
Estimated financial data (e) (USD)
Sales 2023 7 338 M - -
Net income 2023 -974 M - -
Net cash position 2023 6 940 M - -
P/E ratio 2023 -57,0x
Yield 2023 -
Sales 2024 6 632 M - -
Net income 2024 -1 540 M - -
Net cash position 2024 5 889 M - -
P/E ratio 2024 -31,8x
Yield 2024 -
Capitalization 47 884 M 47 884 M -
EV / Sales 2023 5,58x
EV / Sales 2024 6,33x
Nbr of Employees 3 900
Free-Float 91,0%
More Financials
Company
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in... 
Sector
Biotechnology & Medical Research
Calendar
06/08 | 10:30amPresentation
More about the company
Ratings of Moderna, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about MODERNA, INC.
06/07Insider Sell: Moderna
MT
06/07Pfizer, Moderna, BioNTech Sued for Alleged Patent Infringement Over COVID-19 Vaccine
MT
06/06Moderna, Pfizer hit with new patent lawsuits over COVID vaccines
RE
06/06Alnylam Files New COVID-19 Vaccine Infringement Lawsuits Against Pfizer And Moderna
AQ
06/05Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data
RE
06/05Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data
RE
06/05Transcript : Moderna, Inc. - Special Call
CI
06/05Merck & Co/Moderna Combo Cuts Risk of Melanoma Spreading in Mid-stage Study
MT
06/05Cancer drugmakers rise as industry meet fuels investor interest
RE
06/05Moderna, Merck Report Positive Results From Trial of mRNA-4157, Keytruda Combination to..
MT
06/05Insider Sell: Moderna
MT
06/05Moderna and Merck Announces mRNA-4157 (V940) in Combination With KEYTRUDA Demonstrated ..
CI
06/02Insider Sell: Moderna
MT
06/01Promising human antibodies fighting SARS-CoV-2
AQ
06/01US FDA approves Pfizer RSV vaccine a month after greenlighting GSK shot
RE
More news
News in other languages on MODERNA, INC.
06/07Vente d'initié : Moderna
06/07Pfizer, Moderna, BioNTech poursuivis pour violation présumée de brevet sur le vaccin CO..
06/07Principales informations avant-Bourse
06/07Les HUG vont tester un vaccin de Moderna à ARNm prometteur contre le mélanome
06/06EU-Arzneimittelbehörde empfiehlt Anpassung der Corona-Impfstoffe
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
ETFs positioned on MODERNA, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
VanEck Genomics and Healthcare Innovators - USD7.84%5.11%-NC
IShares Nasdaq US Biotechnology - USD6.15%2.88%United_States
VanEck Biotech ETF - USD5.66%1.90%United_States
Invesco Nasdaq Biotechnology ETF - USD5.19%1.86%-United_States
IShares Nasdaq US Biotechnology (D) - USD5.19%2.61%United_States
More ETFs positioned on MODERNA, INC.
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 125,61 $
Average target price 211,96 $
Spread / Average Target 68,7%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
James M. Mock Chief Financial Officer
Noubar B. Afeyan Chairman
Paul Burton Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-30.07%47 884
LONZA GROUP AG28.67%47 689
IQVIA HOLDINGS INC.1.80%38 700
SEAGEN INC.51.54%36 516
ALNYLAM PHARMACEUTICALS, INC.-18.81%23 681
CELLTRION, INC.6.17%18 622
Secure and increase the performance of your investments with our team of experts at your side.
Securing my Investments
fermer